AstraZeneca will withdraw its shares from the NASDAQ listing and join the NYSE in February

AstraZeneca (AZN) announced its move from Nasdaq to the New York Stock Exchange (NYSE) as part of a listing structure unification, Reuters reports.

The company stated that it will delist its U.S. depositary shares (ADS) and debt securities from Nasdaq after the close of trading on January 30, 2026. The direct listing of common shares and debt obligations on NYSE will take effect on February 2, 2026, with the ticker AZN retained.

The decision is part of a shareholder-approved plan to transition from trading ADS to direct trading of common shares with a $0.25 par value. The new structure will allow investors to trade AstraZeneca shares directly on the London Stock Exchange, Nasdaq Stockholm, and NYSE, simplifying access to the company’s shares and reducing operational complexity across different markets.

AstraZeneca remains one of the largest players in the global pharmaceutical sector, focusing on oncology, cardiovascular, respiratory, immunology, and rare diseases. A significant portion of its revenue comes from outside the UK, with the U.S. market accounting for roughly one-third of sales.